Biblioteca Humberto Rosselli Quijano
Información del autor
Autor Bruce G. Pollock |
Documentos disponibles escritos por este autor (4)
Refinar búsquedaAnticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine / K. N. R. Chengappa en Journal of Clinical Psychopharmacology, Año 2000 - Vol. 20 - No. 3 (Junio)
Título : Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine Tipo de documento: texto impreso Autores: K. N. R. Chengappa, Autor ; Bruce G. Pollock, Autor ; Haranath Parepally, Autor Fecha de publicación: 2023 Artículo en la página: pp. 311-316 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Atropina, Enfermedades del sistema nervioso autónomo, Antagonistas colinérgicos, Clozapina, Antagonistas muscarínicos, Pirenzepina, Trastornos psicóticos. Resumen: This study evaluated anticholinergic effects among patients with schizophrenia, schizoaffective disorder, or bipolar I disorder who were receiving either olanzapine (N = 12) or clozapine (N = 12) at standard clinical doses in a naturalistic setting. Serum anticholinergic levels were determined in adult male and female subjects using a radioreceptor binding assay. The Udvalg for Kliniske Undersogelser Scale was used to evaluate anticholinergic side effects clinically, and the Mini-Mental State Examination provided a global cognitive measure. Link: ./index.php?lvl=notice_display&id=31197
in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 3 (Junio) . - pp. 311-316[artículo] Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine [texto impreso] / K. N. R. Chengappa, Autor ; Bruce G. Pollock, Autor ; Haranath Parepally, Autor . - 2023 . - pp. 311-316.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 3 (Junio) . - pp. 311-316
Palabras clave: Antipsicóticos, Atropina, Enfermedades del sistema nervioso autónomo, Antagonistas colinérgicos, Clozapina, Antagonistas muscarínicos, Pirenzepina, Trastornos psicóticos. Resumen: This study evaluated anticholinergic effects among patients with schizophrenia, schizoaffective disorder, or bipolar I disorder who were receiving either olanzapine (N = 12) or clozapine (N = 12) at standard clinical doses in a naturalistic setting. Serum anticholinergic levels were determined in adult male and female subjects using a radioreceptor binding assay. The Udvalg for Kliniske Undersogelser Scale was used to evaluate anticholinergic side effects clinically, and the Mini-Mental State Examination provided a global cognitive measure. Link: ./index.php?lvl=notice_display&id=31197
Título : Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-alzheimer's disease trial Tipo de documento: texto impreso Autores: Alette M. Wessels, Autor ; Bruce G. Pollock, Autor ; Norbert G. Anyama, Autor Fecha de publicación: 2022 Artículo en la página: pp. 683-687 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Enfermedad de Alzheimer, Suspensión del tratamiento, 9-OH risperidona Resumen: Risperidone has been used to treat behavioral symptoms, such as delusions and agitation, in people with Alzheimer's disease. The relationship between magnitude and variability of risperidone and 9-hydroxy risperidone exposure and the relationship with time to discontinuation of the medication were explored. Link: ./index.php?lvl=notice_display&id=29416
in Journal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 6 (Diciembre) . - pp. 683-687[artículo] Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-alzheimer's disease trial [texto impreso] / Alette M. Wessels, Autor ; Bruce G. Pollock, Autor ; Norbert G. Anyama, Autor . - 2022 . - pp. 683-687.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 6 (Diciembre) . - pp. 683-687
Palabras clave: Enfermedad de Alzheimer, Suspensión del tratamiento, 9-OH risperidona Resumen: Risperidone has been used to treat behavioral symptoms, such as delusions and agitation, in people with Alzheimer's disease. The relationship between magnitude and variability of risperidone and 9-hydroxy risperidone exposure and the relationship with time to discontinuation of the medication were explored. Link: ./index.php?lvl=notice_display&id=29416
Título : Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment Tipo de documento: texto impreso Autores: Bruce G. Pollock, Autor ; Fouzia Laghrissi Thode, Autor Fecha de publicación: 2023 Artículo en la página: pp. 137-140 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antidepresivos tricíclicos, Enfermedad Coronaria, Trastorno depresivo, Nortriptilina, Paroxetina. Resumen: This study investigated the effects of antidepressant treatment on platelet activation in depressed patients with ischemic heart disease (IHD). Plasma levels of platelet α-granule release products β-thromboglobulin (BTG) and platelet factor 4 (PF4) were measured in 17 depressed patients with IHD who were treated in a 6-week, double-blind trial with either paroxetine (10 patients) or nortriptyline (7 patients). Link: ./index.php?lvl=notice_display&id=31207
in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 2 (Abril) . - pp. 137-140[artículo] Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment [texto impreso] / Bruce G. Pollock, Autor ; Fouzia Laghrissi Thode, Autor . - 2023 . - pp. 137-140.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 2 (Abril) . - pp. 137-140
Palabras clave: Antidepresivos tricíclicos, Enfermedad Coronaria, Trastorno depresivo, Nortriptilina, Paroxetina. Resumen: This study investigated the effects of antidepressant treatment on platelet activation in depressed patients with ischemic heart disease (IHD). Plasma levels of platelet α-granule release products β-thromboglobulin (BTG) and platelet factor 4 (PF4) were measured in 17 depressed patients with IHD who were treated in a 6-week, double-blind trial with either paroxetine (10 patients) or nortriptyline (7 patients). Link: ./index.php?lvl=notice_display&id=31207
Título : Pharmacologic profile of perphenazine's metabolites Tipo de documento: texto impreso Autores: Robert A. Sweet, Autor ; Bruce G. Pollock, Autor ; Benoit H. Mulsant, Autor Fecha de publicación: 2023 Artículo en la página: pp. 181-187 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Efectos cerebrales, Demencia, Antagonistas de la dopamina, Perfenazina. Resumen: The authors have previously reported that in elderly patients treated with low doses of perphenazine, few extrapyramidal symptoms (EPS) developed in those who were not poor CYP2D6 metabolizers. The authors hypothesized that this atypical side effect profile is due to perphenazine's principal metabolite, n-dealkylperphenazine (DAPZ), which is usually present in vivo at concentrations 1.5 to 2 times that of the parent drug. Link: ./index.php?lvl=notice_display&id=31213
in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 2 (Abril) . - pp. 181-187[artículo] Pharmacologic profile of perphenazine's metabolites [texto impreso] / Robert A. Sweet, Autor ; Bruce G. Pollock, Autor ; Benoit H. Mulsant, Autor . - 2023 . - pp. 181-187.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 2 (Abril) . - pp. 181-187
Palabras clave: Antipsicóticos, Efectos cerebrales, Demencia, Antagonistas de la dopamina, Perfenazina. Resumen: The authors have previously reported that in elderly patients treated with low doses of perphenazine, few extrapyramidal symptoms (EPS) developed in those who were not poor CYP2D6 metabolizers. The authors hypothesized that this atypical side effect profile is due to perphenazine's principal metabolite, n-dealkylperphenazine (DAPZ), which is usually present in vivo at concentrations 1.5 to 2 times that of the parent drug. Link: ./index.php?lvl=notice_display&id=31213
